Table 2.
Clinical and laboratory data of asthmatic patients, according to miR-499A rs3746444 genotypes
| Characteristics | No | rs3746444 genotypes | P value | ||
|---|---|---|---|---|---|
| AA | AG | GG | |||
| Total number (%) | 211 | 34 (16.1) | 86 (40.8) | 91 (43.1) | |
| Mean age, years | |||||
| Children (6–11) | 144 | 24 (16.7) | 61 (42.4) | 59 (41.0) | 0.650 |
| Adolescents (12–18) | 67 | 10 (14.9) | 25 (37.3) | 32 (47.8) | |
| Gender | |||||
| Female | 118 | 18 (15.3) | 53 (44.9) | 47 (39.8) | 0.380 |
| Male | 93 | 16 (17.2) | 33 (35.5) | 44 (47.3) | |
| FH of asthma | 56 | 8 (14.3) | 21 (37.5) | 27 (48.2) | 0.666 |
| Pubertal status | 109 | 19 (17.4) | 46 (42.2) | 44 (40.4) | 0.685 |
| Obesity | 23 | 3 (13.0) | 11 (47.8) | 9 (39.2) | 0.838 |
| Residence | |||||
| Urban | 75 | 12 (16.0) | 29 (38.7) | 34 (45.3) | 0.879 |
| Rural | 136 | 22 (16.2) | 57 (41.9) | 57 (41.9) | |
| Mean age at onset, years | 3.82 ± 1.6 | 3.58 ± 1.9 | 3.25 ± 1.8 | 0.245 | |
| Early (≤3y) | 99 | 10 (10.1) | 39 (39.4) | 50 (50.5) | 0.036 |
| Late (>3y) | 112 | 24 (21.4) | 47 (42.0) | 41 (36.6) | |
| Asthma duration, years | 5.55 ± 2.5 | 5.96 ± 2.3 | 6.23 ± 2.5 | 0.245 | |
| Asthma phenotypes | |||||
| Atopic asthma | 166 | 28 (16.8) | 66 (39.8) | 72 (43.4) | 0.611 |
| Non-atopic asthma | 15 | 4 (26.7) | 5 (33.3) | 6 (40.0) | |
| Aspirin-sensitive asthma | 25 | 1 (4.0) | 13 (52.0) | 11 (44.0) | |
| Exercise-induced asthma | 5 | 1 (20.0) | 2 (40.0) | 2 (40.0) | |
| Symptoms | |||||
| Daytime symptoms >2/week | 103 | 14 (13.6) | 42 (40.8) | 47 (45.6) | 0.581 |
| Nocturnal symptoms | 39 | 6 (15.4) | 18 (46.2) | 15 (38.6) | 0.741 |
| Reliever use >2/week | 74 | 14 (189) | 35 (47.3) | 25 (33.8) | 0.131 |
| Activity limitations | 69 | 11 (15.9) | 28 (40.6) | 30 (43.5) | 0.997 |
| Asthma control | |||||
| Well controlled | 76 | 16 (21.1) | 28 (36.8) | 32 (42.1) | 0.122 |
| Partly controlled | 99 | 9 (9.1) | 44 (44.4) | 46 (46.5) | |
| Uncontrolled | 36 | 9 (25.0) | 14 (38.9) | 13 (36.1) | |
| Asthma severity | |||||
| Mild | 88 | 15 (17.0) | 35 (39.8) | 38 (43.2) | 0.506 |
| Moderate | 90 | 15 (16.7) | 33 (36.7) | 42 (467) | |
| Severe | 33 | 4 (12.1) | 18 (54.5) | 11 (33.3) | |
| Co-morbidities | 105 | 17 (16.2) | 43 (41.0) | 45 (42.8) | 0.997 |
| Airway hyper-responsiveness | |||||
| Normal | 61 | 11 (18.0) | 20 (32.8) | 30 (49.2) | 0.127 |
| Borderline | 61 | 13 (21.3) | 31 (50.8) | 17 (27.9) | |
| Mild/moderate | 54 | 7 (13.0) | 21 (38.9) | 26 (48.1) | |
| Severe | 35 | 3 (8.6) | 14 (40.0) | 18 (51.4) | |
| Lab tests | |||||
| Total IgE (IU/ml) | 211 | 60 (42–121) | 162 (15–122) | 45 (15–120) | 0.307 |
| AEC (×106/L) | 211 | 111 (31.5–340) | 88 (23.7–245) | 65 (25–230) | 0.571 |
Values are shown as mean ± standard deviation, median (quartiles) or as a number (percentage). AEC; Absolute eosinophilic count, FH; family history. Assessment and classifications of asthma were performed based on GINA guidelines [23]. Chi-square, ANOVA, and Kruskal-Wallis tests were used. Bold values indicate significance at p < 0.05